Xin Lang Cai Jing·2025-10-28 08:45Core Viewpoint - Fosun Pharma reported a decline in revenue for Q3 2025, while net profit showed an increase, indicating mixed financial performance [1] Financial Performance - In Q3 2025, the company achieved revenue of 9.879 billion yuan, a year-on-year decrease of 5.46% [1] - The net profit attributable to shareholders for Q3 2025 was 821 million yuan, reflecting a year-on-year increase of 4.52% [1] - Basic earnings per share for Q3 2025 stood at 0.31 yuan [1] - For the first three quarters of 2025, the total revenue reached 29.393 billion yuan, down 4.91% year-on-year [1] - The net profit attributable to shareholders for the first three quarters was 2.523 billion yuan, showing a significant year-on-year increase of 25.50% [1] - Basic earnings per share for the first three quarters was reported at 0.95 yuan [1]